Skip to main content

OSCR Oscar Health, Inc.

Healthcare

30.37 Close 10/30
Since 2024-12-02 +64.8%
Open
30.56
High
30.87
Low
29.94
Prev close
30.79
Volume
3.6M
Amplitude
3.02%
P/E
21.7
P/B
4.5
Revenue YoY (TTM)
+42.8%
52W 10.69 35.01

Is Oscar Health, Inc. a buy? Fundamentals and valuation first

As of 2026-10-30

Valuation: Fair, Quality: Good, Momentum: Strong, Risk / liquidity: Good.

Valuation Fair Free-cash-flow yield is Top, but Price / book is Expensive.
TTM P/E 21.69 57th percentile Pricey
Price / book 4.47 80th percentile Expensive
Free-cash-flow yield (%) 47.23 96th percentile Top
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Good ROE, TTM is Top, but Operating margin, TTM is Average.
ROE, TTM (%) 26.84 86th percentile Top
Operating margin, TTM (%) 4.07 44th percentile Average
FCF margin, TTM (%) 28.3 85th percentile Top
Quality Factor Investing: A US Quality Value Backtest
Growth Neutral Revenue growth, TTM YoY is Top, but Diluted EPS growth, TTM YoY is Lagging.
Revenue growth, TTM YoY (%) 42.82 86th percentile Top
Diluted EPS growth, TTM YoY (%) -284.21 7th percentile Lagging
Momentum Strong All 2 indicators are Top.
60-day return (%) 14.43 89th percentile Top
240-day return (%) 118.8 97th percentile Top
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top, but 60-day annualized volatility is Average.
20-day dollar volume 149,850,235 90th percentile Top
60-day annualized volatility (%) 45.93 52th percentile Average
Factor Investing Explained: 10 Classic Factors in US Stocks

Oscar Health, Inc. (OSCR) today

2 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From Oscar Health, Inc. to every stock like it

AI finds several complementary traits of Oscar Health, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Oscar Health, Inc.

Oscar Health, Inc. (OSCR) peers and tracking

Watchlist

This page refreshes daily after the close. Add Oscar Health, Inc. to your watchlist to track signal changes on your next visit.

Oscar Health, Inc. (OSCR) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 93.72%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
13 historical occurrences (since 2022-08-12)

Average forward return after Top-quintile 6-month momentum

20-day: Win 61.5%, Sample 13, Median +7.06%, Excess +6.07%, Beat mkt rate 53.8%

60-day: Win 53.8%, Sample 13, Median +17.15%, Excess +6.93%, Beat mkt rate 53.8%

120-day: Win 45.5%, Sample 11, Median -3.19%, Excess +14.64%, Beat mkt rate 27.3%

120 days after: historical avg +24.51%

20-day +7.58%
60-day +12.69%
120-day +24.51%
20-day
60-day
120-day
Win
61.5%
53.8%
45.5%
Sample
13
13
11
Median
+7.06%
+17.15%
-3.19%
Excess
+6.07%
+6.93%
+14.64%
Beat mkt rate
53.8%
53.8%
27.3%

Over 11 occurrences, 120-day forward avg gained 24.51%, beat the market by 14.64 pts; win rate 45.5%.

Filed revenue acceleration

Active · now 42.82%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

6 historical occurrences (since 2024-05-07)

Average forward return after Filed revenue acceleration

20-day: Win 66.7%, Sample 6, Median +9.32%, Excess +4.67%, Beat mkt rate 50%

60-day: Win 80%, Sample 5, Median +8.36%, Excess +6.12%, Beat mkt rate 60%

120-day: Win 40%, Sample 5, Median -4.69%, Excess -3.87%, Beat mkt rate 40%

120 days after: historical avg +3.1%

20-day +5.29%
60-day +9.61%
120-day +3.1%
20-day
60-day
120-day
Win
66.7%
80%
40%
Sample
6
5
5
Median
+9.32%
+8.36%
-4.69%
Excess
+4.67%
+6.12%
-3.87%
Beat mkt rate
50%
60%
40%

Over 5 occurrences, 120-day forward avg gained 3.1%, lagged the market by 3.87 pts; win rate 40%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

9 times historically; 60-day forward avg +1.88%, win rate 50%, beating the market by -3.1 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

12 times historically; 60-day forward avg +8.92%, win rate 66.7%, beating the market by +6.96 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.